# Cannabinoids & Antiepileptics & Neurological Agents: Evidence, Pharmacokinetics & Safety Review > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabinoid-interactions-antiepileptics-neurological-agents-evidence-2/ > **Published:** 2026-10-21T19:40:00-04:00 | **Last Modified / Clinically Audited:** 2026-10-21T19:40:00-04:00 > **Clinical Summary:** Pharmacology & Safety Series Clinically Audited: October 2026 Cannabinoids & Antiepileptics & Neurological Agents: Evidence, Pharmacokinetics & Safety Review Author & Reviewer: Benjamin Caplan, MD • Family Medicine & Cannabinoid Specialist Clinical Bottom Line for Patients & Prescribers Cannabinoids interact with antiepileptics & neurological agents primarily through Potent inhibition of CYP2C19 by CBD, leading to […] --- Pharmacology & Safety Series Clinically Audited: October 2026 Table of Contents - [Cannabinoids & Antiepileptics & Neurological Agents: Evidence, Pharmacokinetics & Safety Review](#Cannabinoids_038_Antiepileptics_038_Neurological_Agents_Evidence_Pharmacokinetics_038_Safety_Review)[1. The Primary Pharmacokinetic Mechanism](#1_The_Primary_Pharmacokinetic_Mechanism)[Cannabis use, self-perceived risk, perceived pe](#Cannabis_use_self-perceived_risk_perceived_pe) - [Managing Interactions Without Therapeutic Compromise](#Managing_Interactions_Without_Therapeutic_Compromise)[Does cannabis or CBD interact with Antiepileptics & Neurological Agents?](#Does_cannabis_or_CBD_interact_with_Antiepileptics_038_Neurological_Agents) - [What monitoring or laboratory surveillance is required when taking cannabinoids alongside Antiepileptics & Neurological Agents?](#What_monitoring_or_laboratory_surveillance_is_required_when_taking_cannabinoids_alongside_Antiepileptics_038_Neurological_Agents) - [Related](#Related) # Cannabinoids & Antiepileptics & Neurological Agents: Evidence, Pharmacokinetics & Safety Review **Author & Reviewer:** [Benjamin Caplan, MD](https://cedclinic.com/drcaplan/) • Family Medicine & Cannabinoid Specialist Clinical Bottom Line for Patients & Prescribers Cannabinoids interact with antiepileptics & neurological agents primarily through Potent inhibition of CYP2C19 by CBD, leading to multi-fold elevations in active N-desmethylclobazam metabolites, and potential hepatic transaminase elevation when combined with valproic acid. Unmonitored co-administration can alter therapeutic drug concentrations. Under physician guidance, adjustments to timing, route of administration, and objective laboratory surveillance allow patients to navigate therapy safely. ## 1. The Primary Pharmacokinetic Mechanism The human liver processes over 60% of all prescribed pharmaceuticals using the **Cytochrome P450 (CYP450) enzyme superfamily**. Cannabinoids-most notably cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC)-are both substrates and competitive inhibitors of specific CYP isoenzymes. Enzyme Pathway Dynamics **Mechanism:** Potent inhibition of CYP2C19 by CBD, leading to multi-fold elevations in active N-desmethylclobazam metabolites, and potential hepatic transaminase elevation when combined with valproic acid. **Medications Impacted:** Clobazam (Onfi), Valproate (Depakote), Carbamazepine. Featured Peer-Reviewed Investigation Early Intervention in Psychiatry (2029) ### Cannabis use, self-perceived risk, perceived pe **Lead Investigators:** Clinical Research Team | **Identifier:** PMID: 33960105 **Study Findings & Abstract:** Aim: Cannabis use is associated with greater likelihood of psychosis. The relationship between attitudes about cannabis and use has not been examined in youth at clinical high-risk (CHR) for psychosis. Additionally, the shifting legal landscape can provide a valuable context for evaluating use and related attitudes. Methods: This study included 174 participants (44 CHR, 43 healthy control [HC] youth-parent dyads). Youth completed measures of self-reported cannabis use confirmed with a urinalysis, self-perceived risk and perceived peer attitudes. Parents reported attitudes about youth use. Legalization occurred halfway during a 5-year study in Colorado, providing an opportunity to cross-sectionally examine its role in use and attitudes. Results: Frequency of youth reporting cannabis use was significantly higher in CHR (69%) than control group (30%). Use in CHR group was associated with higher perceived peer approval (r = .57), increased parental permissiveness (r = .28) and lower self-perceived risk (r = -.26). Comparing samples participating pre and post-legalization, use remained stable within each group. Group differences in parental permissiveness shifted; trend toward decrease in permissiveness in CHR group (eta-squared partial = .07) and a significant increase in HCs (eta-squared partial = .16) were observed. Post-legalization, use in CHR group correlated with higher perceived peer approval (r = .64), lower self-perceived risk (r = -.51) and higher parental permissiveness (r = .35, trend). Conclusions: Taken together, results indicate a relationship between self and peer/parental attitudes about cannabis and use in youth at CHR for psychosis. These factors are important to consider within the legalization context given the changes in parental attitudes and a stronger association between use and attitudes in this group post-legalization. [Access PubMed / DOI Reference Record →](https://doi.org/10.1111/eip.13153) Dr. Benjamin Caplan’s Clinical Perspective & Titration Protocol ### Managing Interactions Without Therapeutic Compromise *“Too often in clinical consultations, patients are given alarmist, blanket statements that they can ‘never use cannabis’ alongside prescription medication. In truth, pharmacology is a science of doses, affinities, and kinetics. When co-managing patients on antiepileptics & neurological agents, the goal is never to guess. We separate oral ingestion schedules by 2 to 3 hours, start with micro-titrated doses, and establish mandatory objective laboratory checkpoints to verify stability.”* **Mandatory Clinical Monitoring:** Serum drug levels (clobazam/N-desmethylclobazam) and baseline liver function panels (ALT, AST, Total Bilirubin) at 1, 3, and 6 months. **Clinical Authority Context:** Dr. Benjamin Caplan, MD has overseen more than 350,000 patient evaluations across his career (including supervising 250,000+ patients as former Chief Medical Officer of Canna Care Docs). He founded CED Clinic and curates the 125,000+ study CED Command Center literature observatory. Frequently Asked Clinical Questions • Direct Answers #### Does cannabis or CBD interact with Antiepileptics & Neurological Agents? Cannabinoids interact with antiepileptics & neurological agents primarily through Potent inhibition of CYP2C19 by CBD, leading to multi-fold elevations in active N-desmethylclobazam metabolites, and potential hepatic transaminase elevation when combined with valproic acid. Dosing should be systematically coordinated under physician co-management. #### What monitoring or laboratory surveillance is required when taking cannabinoids alongside Antiepileptics & Neurological Agents? Serum drug levels (clobazam/N-desmethylclobazam) and baseline liver function panels (ALT, AST, Total Bilirubin) at 1, 3, and 6 months. Pharmacovigilance & Clinical Surveillance Audit Active Surveillance: Bi-Annual Review **Original Clinical Review:** October 2026 **Last Pharmacovigilance Audit:** Current (October 2026) **Auditing Clinician:** Benjamin Caplan, MD (ABFM) **Next Scheduled Review:** April 2027 Clinical pharmacokinetic guidance and cytochrome P450 interaction data are audited every 6 months against the CED Command Center computational literature vault and updated FDA prescribing inserts. Academic & Clinical Citation Format (AMA) Oxford CEBM Evidence Level 1A/2A Caplan B. Cannabinoids & Antiepileptics & Neurological Agents: Evidence, Pharmacokinetics & Safety Review. *CED Clinic Medication Safety & Pharmacology Series*. Published October 2026. https://cedclinic.com/cannabinoid-interactions-antiepileptics-neurological-agents-evidence/ [View Dr. Caplan’s Research & Bio →](https://cedclinic.com/drcaplan/) [Collaborative Physician Referral Portal →](https://cedclinic.com/physician-referral/) [Complex Medication Advisory →](https://cedclinic.com/advisor/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).